# Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes

Study · id `cardio:ct-nct01237301` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01237301](<https://clinicaltrials.gov/study/NCT01237301>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01237301

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.

## Technical summary

Registry record NCT01237301. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2014-01-06.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 124 participants (enrolled count; ClinicalTrials.gov record NCT01237301, source copy `cardio:ctgov-nct01237301-2018-10-17`, retrieved 2026-10-26)
- Start date: 2010-10 (registry gives no type) (ClinicalTrials.gov record NCT01237301, source copy `cardio:ctgov-nct01237301-2018-10-17`, retrieved 2026-10-26)
- Primary completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01237301, source copy `cardio:ctgov-nct01237301-2018-10-17`, retrieved 2026-10-26)
- Completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01237301, source copy `cardio:ctgov-nct01237301-2018-10-17`, retrieved 2026-10-26)
- Results first posted: 2014-01-06 (ClinicalTrials.gov record NCT01237301, source copy `cardio:ctgov-nct01237301-2018-10-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01237301, source copy `cardio:ctgov-nct01237301-2018-10-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01237301-2018-10-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes
- Acronym: REACT3
- Condition: Type 2 Diabetes
- Intervention (Device): CGM Group
- Intervention (Device): SMBG Group
- Lead sponsor: HealthPartners Institute
- Lead sponsor class: OTHER
- Collaborator: Roche Diagnostics GmbH
- Collaborator class: INDUSTRY
- Collaborator: International Diabetes Center at Park Nicollet
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: c6ea1b697b14cf3860bb3b8095f77af5cca2ad298ec4495a1b7cb008efda4bce
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
